Comparison of Scalp Microbiota of the Psoriasis and Seborrheic Dermatitis Patients
Comparison of Scalp Microbiota of the Patients With Psoriasis Vulgaris and Seborrheic Dermatitis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Istanbul, Turkey
- Melek Aslan Kayıran
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with scalp psoriasis
- Patients with seborrheic dermatitis
- Agree to participate in research 4 - Do not use any drugs for their disease topically or systemically for two months
Exclusion Criteria:
- Patients who do not want to participate in the study
- Patients with psoriasis vulgaris or seborrheic dermatitis that does not effect scalp.
- Those with chronic diseases that may affect skin microbiome
- Patients using antibiotics, antifungal or antiviral therapy for any reason for the last one month.
- Patients who are using topical or systemic drugs for their illness
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Control Group
|
The scalp microbiota
|
|
Psoriasis Vulgaris patients-Lesion
|
The scalp microbiota
|
|
Psoriasis Vulgaris patients-Lesion free
|
The scalp microbiota
|
|
Seborrheic Dermatitis-Lesion
|
The scalp microbiota
|
|
Seborrheic Dermatitis-Lesion free
|
The scalp microbiota
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The scalp microbiota of the patients with psoriasis and seborrheic dermatitis
Time Frame: 6 months
|
The aim of this study is to compare the scalp microbiota of psoriasis vulgaris and seborrheic dermatitis both the lesion and lesion-free parts and also the control group and to assess their role on etiopathogenesis. Determining the microbiota of this region which is frequently involved and resistant to treatment may change the treatment approach. In addition, scalp microbiome of seborrheic dermatitis may be a causal factor of rapid relapse after treatment. The similarities between the microbiota of the psoriasis vulgaris and seborrheic dermatitis cases with only scalp involvement can guide us not only for the diagnosis but also the treatment. There are a few reports about the role of Malassezia subgroups in the pathogenesis, but it is known that there are many different flora members on the scalp. Exposing these can change both our diagnosis and treatment options. |
6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The differences between the scalp microbiota of different countries
Time Frame: 6 months
|
Does the microbiota of the patients change between the countries?
To our knowledge, there is no similar studies in present.
Presenting the scalp microbiome of Turkish population can be a start to understand whether there is a difference in terms of the countries.
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IstanbulMU2
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Microbial Colonization
-
NCT03302715CompletedMicrobial Colonization and Colorectal Disease
-
NCT07196969CompletedOral Microbial Colonization | Periodontal Health | Periodontal Parameters
-
NCT01038479UnknownDental Caries | Oral Microbial Colonization
-
NCT06274931RecruitingPneumonia | Microbial Colonization | Microbial Disease
-
NCT06327841CompletedGingivitis | Dental Plaque | Oral Microbial Colonization
-
NCT06841380CompletedGingivitis | Dental Plaque | Oral Microbial Colonization
-
NCT06405958Not yet recruitingMicrobial Colonization
-
NCT06264219RecruitingMicrobial Colonization
-
NCT05750381Recruiting
Clinical Trials on Microbiota
-
NCT03298048Terminated
-
NCT02449174Completed
-
NCT04899869CompletedIrritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome Mixed
-
NCT04251767WithdrawnCOVID-19 Complicated With Refractory Intestinal Infections
-
NCT06708676Not yet recruitingSolid Organ Transplant Complications
-
NCT03764748RecruitingTourette Syndrome
-
NCT06376331RecruitingAttention-deficit/Hyperactivity Disorder